Georgios Kokkotis, Evanthia Zampeli, Maria Tzouvala, Ioannis Giotis, Philippos Orfanos, Vassiliki Benetou, Maria Stoupaki, Nikolaos Leontidis, Georgios Leonidakis, Vassiliki Kitsou, Aikaterini Gaki, Pagona Lagiou, Spyridon Michopoulos, Giorgos Bamias
OBJECTIVES: Vedolizumab is a mAb used for the treatment of moderate to severe ulcerative colitis and Crohn's disease. There is evidence that administration of vedolizumab has been associated with either new onset or reactivation of extra-intestinal manifestations, among which arthralgia is the most prominent. We aimed to study the incidence, characteristics and predictors for the occurrence of arthralgias in patients with inflammatory bowel disease (IBD) who receive vedolizumab. METHODS: A retrospective cohort study was implemented in patients with IBD...
April 1, 2023: European Journal of Gastroenterology & Hepatology